Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Holst, J. J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Pharmacology of GLP-1-based therapies

Jens Juul Holst

Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Denmark, holst{at}mfi.ku.dk

Glucagon-like peptide-1 GLP-1 is a naturally occurring 30-amino acid peptide synthesised in intestinal endocrine L cells. GLP-1 mediates glucose homeostasis through stimulation of glucose-dependent insulin secretion, biosynthesis of insulin and inhibition of glucagon secretion. These effects have potential clinical value in type 2 diabetes. However, because native GLP-1 is rapidly degraded to its inactive form by dipeptidyl peptidase-4 (DPP-4), it has a short half-life in vivo . Strategies to overcome this therapeutic limitation include developing GLP-1 mimetics and analogues with longer half-lives and to inhibit DPP-4. Exenatide (exendin-4) is a 39-amino acid peptide originally derived from the venom of the Gila monster lizard, and shares a 53% sequence identity with human GLP-1. Exenatide has a longer circulating half-life, reflecting relative resistance to DPP-4 degradation, and is administered twice daily. Liraglutide is a once-daily human GLP-1 analogue with high (97%) sequence identity. The specific structural modifications that characterise liraglutide result in increased self-association (allowing slow absorption from the subcutaneous depot), promote albumin binding and reduce susceptibility to DPP-4, giving liraglutide a half-life of 13 hours after once-daily administration. Preliminary studies of exenatide and liraglutide show clinically relevant reductions in glycosylated haemoglobin A1c (HbA1c) compared with placebo, without hypoglycaemia and with weight loss of up to 3 kg. DPP-4 inhibitors, such as vildagliptin (not available in the USA) and sitagliptin can help stabilise postprandial GLP-1 levels and thus produce desirable effects on insulin and glucagon production. The potential for weight reduction with DPP-4 inhibitors appears limited, perhaps reflecting the limited increase in GLP-1 levels achieved with these agents. Br J Diabetes Vasc Dis, 2008; 8 (Suppl 2) : S10—S18

Key Words: dipeptidyl peptidase-4 • glucagon-like peptide-1 • glucagon • incretin • insulin release

References

  • Holst JJ, Bersani M., Johnsen AH et al. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994;269:18827-33.[Abstract/Free Full Text]
  • Chen YE, Drucker DJ Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108-15.[Abstract/Free Full Text]
  • Mojsov S., Heinrich G., Wilson IB et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986;261:11880-9.[Abstract/Free Full Text]
  • Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 1988;263:13475-8.[Abstract/Free Full Text]
  • rskov C., Bersani M., Johnsen AH et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989;264:12826-9.[Abstract/Free Full Text]
  • Holst JJ The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.[Abstract/Free Full Text]
  • Buhl T., Thim L., Kofod H. et al. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem 1988;263:8621-4.[Abstract/Free Full Text]
  • rskov C., Buhl T., Rabenhøj L. et al. Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. FEBS Lett 1989;247:193-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kervran A., Blache P., Bataille D. Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. Endocrinology 1987;121:704-13.[Abstract/Free Full Text]
  • Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40.[Abstract/Free Full Text]
  • Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003;3:365-72.[Medline] [Order article via Infotrieve]
  • Drucker DJ Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farilla L., Bulotta A., Hirshberg B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Trümper A., Trümper K., Trusheim H. et al. Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-70.[Abstract/Free Full Text]
  • Trümper A., Trümper K., Hörsch D. Mechanisms of mitogenic and antiapoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells. J Endocrinol 2002;174:233-46.[Abstract]
  • Wideman RD, Kieffer TJ Glucose-dependent insulinotropic peptide as a regulator of beta cell function and fate. Horm Metab Res 2004; 36:782-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nauck MA, Niedereichholz U., Ettler R. et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 1997;273:981-8.
  • Tourrel C., Bailbe D., Meile MJ et al. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenisis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70.[Abstract/Free Full Text]
  • Perfetti R., Zhou J., Doyle ME, Egan JM Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose intolerant rats. Endocrinology 2000;141:4600-5.[Abstract/Free Full Text]
  • Farilla L., Hui H., Bertolotto C. et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408.[Abstract/Free Full Text]
  • Meier JJ, Goetze O., Anstipp J. et al. Gastric inhibitory peptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004;286:E621-5.[Abstract/Free Full Text]
  • Nauck MA, Heimesaat MM, rskov C. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Vilsbøll T., Holst JJ Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • rskov C., Wettergren A., Holst JJ Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31:665-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Vilsbøll T., Krarup T., Madsbad S., Holst JJ Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Toft-Nielsen M-B., Damholt MB, Madsbad S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.[Abstract/Free Full Text]
  • Vilsbøll T., Krarup T., Madsbad S., Holst JJ Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Elahi D., McAloon-Dyke M., Fukagawa NK et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Højberg PV, Visbøl T., Bache M. et al. Incretin effects: clinical. 43rd European Association for the Study of Diabetes Annual Meeting, 17-21 September 2007, Amsterdam, The Netherlands. Abstract OP45.
  • Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and βcell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Buteau, J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Buteau J., El-Assaad W., Rhodes CJ et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Verdich C., Flint A., Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.[Abstract/Free Full Text]
  • Bullock BP, Heller RS, Habener JF Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-78.[Abstract]
  • Fortuin NJ, Hood WP Jr, Craige E. Evaluation of left ventricular function by echocardiography. Circulation 1972;46:26-35.[Abstract/Free Full Text]
  • Gros R., You X., Baggio LL et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-52.[Abstract/Free Full Text]
  • Yu M., Moreno C., Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nikolaidis LA, Elahi D., Hentosz T. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61.[Abstract/Free Full Text]
  • Bose AK, Mocanu MM, Carr RD et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51.[Abstract/Free Full Text]
  • Nikolaidis LA, Mankad S., Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5.[Abstract/Free Full Text]
  • Nyström T., Gutniak MK, Zhang Q. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-15.[Abstract/Free Full Text]
  • Deacon CF, Johnsen AH, Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7.[Abstract]
  • Vilsbøll T., Agersø H., Krarup T., Holst JJ Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4.[Abstract/Free Full Text]
  • Eng J., Kleinman WA, Singh L. et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5.[Abstract/Free Full Text]
  • Drucker DJ The biology of incretin hormones. Cell Metab 2006;3:153-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kolterman OG, Kim DD, Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81.[Abstract/Free Full Text]
  • Byetta® exenatide injection [prescribing information]. San Diego: Amylin Pharmaceuticals, Inc., 2007
  • Kim D., MacConell L., Zhuang D. et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93.[Abstract/Free Full Text]
  • Buse JB, Henry RR, Han J. et al. For the Exenatide-113 Clincial Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.[Abstract/Free Full Text]
  • DeFronzo RA, Ratner RE, Han J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.[Abstract/Free Full Text]
  • Kendall DM, Riddle MC, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.[Abstract/Free Full Text]
  • Blonde L., Klein EJ, Han J. et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holst JJ Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004;9:155-66.[CrossRef][Medline] [Order article via Infotrieve]
  • Agersø H., Jensen LB, Elbrønd B. et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Elbrønd B., Jakobsen G., Larsen S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404.[Abstract/Free Full Text]
  • Chang AM, Jakobsen G., Sturis J. et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91.[Abstract/Free Full Text]
  • Choukem SP, Gautier J-F. How do different GLP-1 mimetics differ in their actions? Curr Diab Rep 2006;6:365-72.[CrossRef][Medline] [Order article via Infotrieve]
  • Feng J., Zhang Z., Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Amori RE, Lau J., Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA 2007;298:194-206.[Abstract/Free Full Text]
  • Nauck MA, Meininger G., Sheng D. et al. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosenstock J., Baron MA, Dejager S. et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:217-23.[Abstract/Free Full Text]
  • Rosenstock J., Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schweizer A., Couturier A., Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007; 24:955-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2 Suppl, S10-S18 (2008)
DOI: 10.1177/1474651408100523
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Holst, J. J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?